<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35466411</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Open-label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>71</StartPage><EndPage>75</EndPage><MedlinePgn>71-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27560</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Neuronal hyperexcitability (manifested by cramps) plays a pathological role in amyotrophic lateral sclerosis (ALS), and drugs affecting it may help symptomatic management and slow disease progression. We aimed to determine safety and tolerability of two doses of ranolazine in patients with ALS and evaluate for preliminary evidence of drug-target engagement by assessing muscle cramp characteristics.</AbstractText><AbstractText Label="METHODS">We performed an open-label dose-ascending study of ranolazine in 14 individuals with ALS in two sequential cohorts: 500&#x2009;mg (cohort 1) and 1000&#x2009;mg (cohort 2) orally twice daily. Each had a 2-week run-in period, 4-week drug administration, and 6-week safety follow-up. Primary outcome was safety and tolerability. Exploratory measures included cramp frequency and severity, fasciculation frequency, cramp potential duration, ALS Functional Rating Scale---Revised score, and forced vital capacity.</AbstractText><AbstractText Label="RESULTS">Six and eight participants were enrolled in cohorts 1 and 2, respectively. There were no serious adverse events. Two subjects in cohort 2 discontinued the drug due to constipation. The most frequent drug-related adverse event was gastrointestinal (40%). Cramp frequency decreased by 54.8% (95% confidence interval [CI], 39%-70.8%) and severity decreased by 46.3% (95% CI, 29.5-63.3%), which appeared to be dose-dependent, with decreased awakening due to cramps. Other outcomes showed no change.</AbstractText><AbstractText Label="DISCUSSION">Ranolazine was well tolerated in ALS up to 2000&#x2009;mg/day, with gastrointestinal side effects being the most frequent. Ranolazine reduced cramp frequency and severity, supporting its investigation for muscle cramps in a future placebo-controlled trial.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chandrashekhar</LastName><ForeName>Swathy</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2389-5364</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamasaki</LastName><ForeName>Anai C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clay</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCalley</LastName><ForeName>Ayla</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herbelin</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasnoor</LastName><ForeName>Mamatha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawdat</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimachkie</LastName><ForeName>Mazen M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barohn</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Missouri System, Columbia, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Statland</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0790-5315</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>#UL1TR002366</GrantID><Agency>National Center for Advancing Translational Sciences (CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute)</Agency><Country/></Grant><Grant><GrantID>#UL1TR002366</GrantID><Agency>University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute)</Agency><Country/></Grant><Grant><GrantID>Gilead Sciences Inc. provided the study drug</GrantID><Agency>Gilead Sciences</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>A6IEZ5M406</RegistryNumber><NameOfSubstance UI="D000069458">Ranolazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009120" MajorTopicYN="Y">Muscle Cramp</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069458" MajorTopicYN="N">Ranolazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">cramps</Keyword><Keyword MajorTopicYN="N">nerve excitability</Keyword></KeywordList><CoiStatement><b>Potential Conflicts of Interest</b>: None of the authors have any relevant financial disclosures or conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35466411</ArticleId><ArticleId IdType="mid">NIHMS1800948</ArticleId><ArticleId IdType="pmc">PMC9197965</ArticleId><ArticleId IdType="doi">10.1002/mus.27560</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Caress JB, Ciarlone SL, Sullivan EA, Griffin LP, Cartwright MS. Natural history of muscle cramps in amyotrophic lateral sclerosis. Muscle Nerve. 2016. Apr;53(4):513&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4775451</ArticleId><ArticleId IdType="pubmed">26332705</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens HE, Joyce NC, Oskarsson B. National Study of Muscle Cramps in ALS in the USA. Amyotroph Lateral Scler Frontotemporal Degener. 2017. Feb;18(1&#x2013;2):32&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575819</ArticleId><ArticleId IdType="pubmed">27978764</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunes ZI, Kan VWY, Ye X, Liebscher S. Exciting Complexity: The Role of Motor Circuit Elements in ALS Pathophysiology. Front Neurosci. 2020. Jun 17;14:573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311855</ArticleId><ArticleId IdType="pubmed">32625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012. Apr 18;(4):CD004157.</Citation><ArticleIdList><ArticleId IdType="pubmed">22513921</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Moore D, Mozaffar T, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve. 2018. Mar 6:10.1002/mus.26117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26117</ArticleId><ArticleId IdType="pmc">PMC6126993</ArticleId><ArticleId IdType="pubmed">29510461</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, Macklin EA, Simmons Z, et al. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016. Apr 19;86(16):1474&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836879</ArticleId><ArticleId IdType="pubmed">26911633</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, Macklin EA, McIlduff CE, et al. Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle Nerve. 2021. Mar;63(3):371&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8513796</ArticleId><ArticleId IdType="pubmed">33340120</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldakkak M, Stowe DF, Camara AK. Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris. Clin Med Insights Ther. 2013. Jan 15;2013(5):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932785</ArticleId><ArticleId IdType="pubmed">24574825</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak KR, Norman J, Mitchell JR, Pinter MJ, Rich MM. Sodium channel slow inactivation as a therapeutic target for myotonia congenita. Ann Neurol. 2015. Feb;77(2):320&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315705</ArticleId><ArticleId IdType="pubmed">25515836</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000. Dec;1(5):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999. Oct 31;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzberg H, Kokokyi S, Halpern E, et al. Prevalence of muscle cramps in patients with diabetes. Diabetes Care. 2014;37(1):e17&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24356604</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji Y, Noto YI, Shiga K, Teramukai S, Nakagawa M, Mizuno T. A muscle ultrasound score in the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol. 2017. Jun;128(6):1069&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">28343888</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M, Carvalho Md. Muscle ultrasound detects fasciculations and facilitates diagnosis in ALS. Neurology. 2011. Oct 18;77(16):1508&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21940612</ArticleId></ArticleIdList></Reference><Reference><Citation>Samara VC, Jerant P, Gibson S, Bromberg M. Bowel, bladder, and sudomotor symptoms in ALS patients. J Neurol Sci. 2021. Aug 15;427:117543.</Citation><ArticleIdList><ArticleId IdType="pubmed">34182195</ArticleId></ArticleIdList></Reference><Reference><Citation>Paci M, Passini E, Severi S, Hyttinen J, Rodriguez B. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach. Heart Rhythm. 2017. Nov;14(11):1704&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668441</ArticleId><ArticleId IdType="pubmed">28756098</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S, Salvatori I, Giacovazzo G, et al. Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target. iScience. 2020. May 22;23(5):101087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200935</ArticleId><ArticleId IdType="pubmed">32371370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>